Extent of Digital Health Fragmentation and Potential Implications for Antimicrobial Prescribing: Rapid Evidence Review

By: Verena Schneider · Akish Luintel · Bethan Balch · Shivani Gangadia · Grainne Brady · Emma McGuire · Gwenan M Knight · Laura Shallcross · Steve Harris · Cecilia Vindrola-Padros

7 October 2026 at 03:30

Background: Prior microbiology results, resistance patterns, and antimicrobial exposure are central to safe and effective antimicrobial prescribing. Digital health fragmentation refers to the dispersal of patient data across multiple electronic systems and the associated challenge of accessing complete information at the point of care. Antimicrobial prescribing for infections represents a critical use case to investigate the impact of digital health fragmentation on patient care. While interoperability has been studied in the context of patient safety, no review has described digital health fragmentation within the United Kingdom and examined its impact on antimicrobial prescribing and antimicrobial stewardship (AMS). Objective: This study aimed to (1) characterize the extent of digital health fragmentation in the United Kingdom, (2) summarize the available evidence on its impact on AMS and prescribing practices in high-income countries, and (3) identify potential solutions. Methods: A rapid review of the peer-reviewed literature was conducted following published guidance for rapid reviews and the PRISMA (Preferred Reporting Items of Systematic Reviews and Meta-Analyses) statement. MEDLINE ALL and PsycInfo were searched on August 19, 2025, using search terms relating to digital health fragmentation or interoperability, patient safety, and antimicrobial use. Searches were limited to English-language publications from 2015 (for characterizing the recent trends or current state of digital health fragmentation in the United Kingdom) or 2010 onward (for AMS-related impacts and solutions). Screening was conducted by 4 researchers following predefined inclusion and exclusion criteria. Extracted data were synthesized narratively through framework analysis. Study quality was appraised using the Mixed Methods Appraisal Tool. Results: Fourteen studies met the inclusion criteria. Ten studies described the extent and nature of digital health fragmentation in the United Kingdom. Digital health fragmentation affects a large number of patients and is linked to clinical care efficiency, quality, and safety risks, including limited access to external clinical records, missing or incomplete information, duplicate investigations, delays in decision‑making, and substantial time spent searching for data. Evidence specific to antimicrobial prescribing was limited (4 studies) but indicated that AMS relies on information spread across multiple systems, with poor interoperability disrupting workflows, hindering communication, and undermining stewardship activities. Only 1 study reported the development of a digital tool designed to address digital health fragmentation and support AMS. Conclusions: Digital health fragmentation negatively affects patient care across the United Kingdom, yet evidence on how it impacts AMS remains scarce. Given the urgency of the global antimicrobial resistance crisis, future research should therefore quantify the scale and impact of digital health fragmentation for AMS to inform investment and innovation in digital infrastructure and clinical-supportive solutions. Trial Registration: PROSPERO CRD420251126067; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251126067

Linking Dispense Data to Electronic Health Orders: Tutorial for Querying Commercial Pharmacy Databases to Support Systemwide Quality Improvement

Journal of Medical Internet Research

By: Benjamin Michaels · Jessica Pourian

7 October 2026 at 03:15

Background: Assessing medication adherence is central to quality care, yet linking electronic health record (EHR) medication orders to outpatient pharmacy dispense data remains technically complex. Objective: This study aimed to present a generalized, reproducible tutorial for linking EHR medication orders to pharmacy dispense data that can be used to assess medication dispense proportions. Methods: We developed and validated a structured query approach to link EHR medication orders to external pharmacy dispense data using patient identifiers, medication-level identifiers, pharmacy identifiers, and temporal constraints. The tutorial emphasizes key design decisions, including handling multiple triggering events, deduplication across vendors, and managing formulation changes. A retrospective cohort of pediatric acute otitis media encounters (January 1, 2021, to January 1, 2024) was used as an illustrative example. Results: Overall, 98.3% (302/307) of pharmacies in the cohort returned at least 1 dispense record during the study period and were therefore classified as reporting pharmacies. Among 3404 orders, 2616 (76.9%) had a recorded dispense. Conclusions: EHR-integrated pharmacy data provide a feasible, timely proxy for assessing medication adherence. This tutorial provides a scalable framework for linking EHR and pharmacy data for medication adherence studies, while highlighting key methodological considerations for SQL coding.

Development and Preliminary Evaluation of a Conversational Agent Delivering Problem-Solving Therapy for Family Caregivers of Children With a Chronic Health Condition: Multiphase Mixed Methods Study

Journal of Medical Internet Research

By: Weichao Yuwen · Liying Wang · Serena Jinchen Xie · Myra Divina · Xuehong Fan · William Kearns · Teresa M Ward

7 October 2026 at 03:00

Background: Family caregivers of children with chronic health conditions experience substantial physical and mental health burdens, including burnout, anxiety, depression, fatigue, and sleep disturbances. Despite this need, validated digital mental health tools tailored to family caregivers remain limited. AI-powered conversational agents offer a promising approach for delivering on-demand, personalized mental health support, yet development and evaluation frameworks for this population are lacking. Objective: This paper describes the iterative development and formative evaluation of COCO (Caring of Caregivers Online), a conversational agent designed for family caregivers of children with chronic health conditions. COCO integrates problem-solving therapy (PST) and motivational interviewing (MI) within a human-in-the-loop development framework that progressed from rule-based interactions to a large language model (LLM)–powered conversational agent. Methods: COCO was developed across four phases: (1) caregiver persona and dialogue development based on PST and MI; (2) usability testing of a low-fidelity prototype with standardized patients in a single session of PST; (3) usability testing of a high-fidelity prototype with caregivers in a single session of PST (n=38); (4) integration of an LLM into COCO. The Wizard-of-Oz method was used across phases 2 and 3 to collect naturalistic dialogues and refine COCO’s conversational design. In phase 3, usability of COCO was assessed using the System Usability Scale (SUS). Caregiver emotions were measured before and after the session using 6 subscales of the PANAS-X. In phase 4, GPT-4 was integrated into COCO with few-shot learning and evaluated by research team members using the caregiver personas. Descriptive statistics were used to summarize quantitative measures. The MI principles and techniques used by COCO across the 4 phases were coded using the . Results: In phase 1, 4 gold-standard dialogues were developed using caregiver personas. In phase 2, standardized patients described COCO as validating and identified its problem-solving and on-demand support as helpful for caregivers. In phase 3, COCO-Wizard-of-Oz achieved a mean SUS score of 75.6% (SD 12.9%), reflecting acceptable usability. Participants demonstrated significant improvement in negative affect, sadness, guilt, and fatigue following PST sessions (

Same-Patient, Same–Time Point Evidence for Radiomics Benchmarking

Journal of Medical Internet Research

By: Wenze Kan · Haoliang Pei · Mingxin Zhang

7 October 2026 at 02:45

This letter examines the interpretation and clinical translation of a meta-analysis of radiomics-based artificial intelligence (AI) for predicting pathological response after neoadjuvant immunochemotherapy in resectable non–small cell lung cancer. We highlight that the conventional-response comparator combines PERCIST and RECIST 1.1 assessments from the same 36-patient cohort, whereas the AI estimates arise from unmatched cohorts; consequently, the reported denominator and Z tests do not establish comparative superiority. We further consider how restriction to patients who reached resection and variation in imaging timepoints narrow the clinical estimand and limit inference about earlier treatment redirection. Clarification of the RECIST and error-direction examples is also warranted. We propose same-patient comparisons in treatment-initiation cohorts using fixed imaging times, locked thresholds, explicit primary-tumor and nodal labels, and calibration and net-benefit analyses at prespecified clinical thresholds.

User Experiences With a Social Robot for Cardiometabolic Risk Assessment in a Community Setting in Uppsala, Sweden: Qualitative Semistructured Interview Study

Journal of Medical Internet Research

By: Solveig Dolores Bruchhof · Helle Mölsted Alvesson · Jonas Idevall Hagren · Katie Winkle · Laran Matta · Marcus Göransson · Steve McKeever · Meena Daivadanam

7 October 2026 at 02:45

Background: Cardiometabolic diseases (CMDs) are a major health concern worldwide, with people living in socioeconomically disadvantaged areas being disproportionately affected. Knowing one’s risk status for developing a CMD can help individuals in delaying or preventing the disease. Innovative tools and strategies such as the use of AI-based technology are needed to improve inclusivity, cost-effectiveness, and sustainability of screening processes. Objective: This study aimed to assess users’ perceptions of the usability and acceptance of the social robot “Furhat” for cardiometabolic risk assessment within a socioeconomically disadvantaged community in Uppsala, Sweden. Methods: In this qualitative study, 13 semistructured interviews were conducted with participants living in socially disadvantaged areas within Uppsala, after they completed a CMD risk assessment delivered by the social robot. The study was conducted in one of the socioeconomically disadvantaged areas in Uppsala from October 19 to 26, 2023. Participants were purposefully sampled at different community events via phone or on the street to achieve the desired variation regarding personal characteristics such as age, gender, or area of living. The used interview guide for this study consisted of questions regarding the demographics, participants’ experiences with the robot screening, and suggestions for improvements. A framework analysis approach was applied to the data. Results: Two themes were developed. The first theme includes participants’ perceptions of who would use the robot and why, if it was installed in the community. Participants perceived older individuals, immigrants, and, in some instances, women to be less interested in the robot screening or as having a harder time participating in it. However, there were between-group variations, especially among men and women, with participants often discounting opinions ascribed to their group by others. The second theme captures participants’ actual experiences of the interaction with the social robot once they have started the interaction. Although participants enjoyed the interaction with the robot, perceived it as nonjudgmental, and would recommend it to others, most would prefer conducting the screening with a human. Two major contributors for this preference were language barriers experienced during the robot-participant interaction, as well as their wish for more interactive, emotionally responsive, and communicative features of the robot. Conclusions: This study provides insights into users’ perceptions of the usability and acceptance of a social robot for risk assessment in a community context, which can help inform the further development of this technology for health screening in a community context. In the future, the robot could be further developed to conduct risk assessments in multiple languages and offer a broader service to users, such as providing appropriate information related to healthy and active living.

Effects of Virtual Reality on Pain, Anxiety, and Fear During Thyroid Fine-Needle Aspiration Biopsy: Open-Label Randomized Controlled Trial

Journal of Medical Internet Research

By: Emine Karadeniz · Hamdiye Arda · Esma Gülsun Arslan Cellat

7 October 2026 at 00:00

Background: Thyroid fine-needle aspiration biopsy (FNAB) is a commonly used diagnostic procedure in patients with suspected thyroid cancer; however, it may induce pain, anxiety, and fear during the procedure. Objective: This open-label randomized controlled trial aimed to evaluate the effect of virtual reality (VR) on pain as the primary outcome and anxiety and fear of pain as secondary outcomes in patients undergoing thyroid FNAB. Methods: The study was conducted between January 19, 2025, and April 30, 2025, at Gaziantep City Hospital, Türkiye. A total of 100 patients with suspected thyroid nodules were randomly assigned to either a VR intervention group (n=50) or a control group (n=50). Data were collected using a patient information form, the visual analog scale (VAS), the Beck Anxiety Inventory (BAI), and the Fear of Pain Questionnaire-III (FPQ-III). Results: After adjustment for baseline pain, previous thyroid mass diagnosis, and voice tone changes, the VR group had statistically significantly lower postintervention pain scores than the control group (adjusted mean 3.627 vs 4.493; F_1,95=4.021; P=.048; partial η²=0.041). However, the unadjusted between-group comparison for pain was not statistically significant (P=.12), and the unadjusted effect size was small, with a 95% CI that crossed 0 (Cohen d=−0.33, 95% CI −0.72 to 0.07). No statistically significant adjusted between-group differences were observed for anxiety (P=.48) or fear of pain (P=.07). Unadjusted standardized between-group effect sizes were also small for anxiety (d=−0.17) and fear of pain (d=−0.11). Conclusions: The adjusted analysis suggested a small reduction in procedural pain with VR; however, the between-group difference was not statistically significant in the unadjusted analysis and reached statistical significance only after adjustment for baseline pain and 2 nonprespecified covariates selected on the basis of observed baseline imbalance. Moreover, the observed adjusted effect (f=0.207) was smaller than the minimum effect size the trial was powered to detect (f=0.283). No statistically significant adjusted between-group effects were found for anxiety or fear of pain. Therefore, the potential analgesic effect of VR should be interpreted cautiously and confirmed in larger, adequately powered trials. Trial Registration: ClinicalTrials.gov NCT06792929; https://clinicaltrials.gov/study/NCT06792929

Metal–organic framework nanovaccines for systemic tumour regression

Nature Biomedical Engineering

By: Xiaomin Jiang · Chaoyu Wang · Kaiting Yang · Langston Tillman · Elizabeth J. Lin · András Piffkó · Chuangyu Wen · Tomas Germanas · Jinhong Li · Xin Ma · Hua Laura Liang · Ralph R. Weichselbaum · Wenbin Lin

6 October 2026 at 08:00

Nature Biomedical Engineering, Published online: 06 October 2026; doi:10.1038/s41551-026-01786-5

A nanoscale metal–organic framework (MOF)-based cancer vaccine platform enables coordinated antigen presentation and innate immune activation, resulting in tumour regression, immune memory and protection against metastasis.

Realignment of representational drift in mouse visual cortex via flexible electrode arrays

Nature Biomedical Engineering

By: Hao Shen · Siyuan Zhao · Arnau Marin-Llobet · Shanshan Qin · Shouhao Jiang · Xin Tang · Madeleine Lee · Xinhe Zhang · Jaeyong Lee · Juntao Chen · Jia Liu

6 October 2026 at 08:00

Nature Biomedical Engineering, Published online: 06 October 2026; doi:10.1038/s41551-026-01780-x

A long-term flexible electrode array system stably tracks individual neurons for months, revealing intrinsic drift in visual evoked neural activity and potentiating durable cross-session and cross-animal decoding.

LLM-derived narrative metrics in chronic pain: convergent validity and novel cognitive constructs

npj Digital Medicine

By: Raquel Norel · Zhengwu Zhang · Jennifer Gewandter · Judith Naddour · Chadi G. Abdallah · Zhiyao Duan · Guillermo Cecchi · Paul Geha

6 October 2026 at 08:00

npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03359-x

LLM-derived narrative metrics in chronic pain: convergent validity and novel cognitive constructs

SPIRIT-CONSORT-ELM: element-level annotated dataset and large language model approach for assessing randomized controlled trial reporting

npj Digital Medicine

By: Lan Jiang · Xiangji Ying · Andrew W. Brown · Mengfei Lan · Wenxuan Song · Joe D. Menke · Colby J. Vorland · Evan Mayo-Wilson · Halil Kilicoglu

6 October 2026 at 08:00

npj Digital Medicine, Published online: 06 October 2026; doi:10.1038/s41746-026-03318-6

SPIRIT-CONSORT-ELM: element-level annotated dataset and large language model approach for assessing randomized controlled trial reporting

A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring

Omics in Hepatocellular

By: Tu Nguyen · Van-Anh Nguyen Hoang · Cang Huynh · Vy Nguyen · Son-Nam H Le · Quang Thinh Trac · Thien-Phuc Nguyen Hoang · Nhat-Anh Dao · Minh Tran Binh Nguyen · Nam Hb Tran · Duy Minh Phan · Hoa Giang · Hoai-Nghia Nguyen · Lan N Tu

5 October 2026 at 18:00

J Liq Biopsy. 2026 Sep 19;14:100496. doi: 10.1016/j.jlb.2026.100496. eCollection 2026 Dec.

ABSTRACT

BACKGROUND: Circulating tumor DNA (ctDNA) analysis has revolutionized minimal residual disease (MRD) monitoring, but conventional tumor-informed amplicon-based sequencing (AMP) is limited by the narrow variant capacity and diversity. Hybrid capture-based sequencing (HYB) is more versatile and enables both tumor-informed and tumor-naïve liquid biopsy profiling.

METHODS: We analytically validated the performance of our novel HYB workflow and VarSURE variant calling pipeline, using reference standards (n = 6), plasma samples of cancer patients (n = 75) and healthy donors (n = 90). Genome-wide (GW) non-mutation features including copy number alterations, fragmentomics, and end-motif signatures were also evaluated to enhance ctDNA-MRD detection. Clinical performance was directly compared against our legacy AMP method (K-TRACK, Gene Solutions), using pre-treatment blood samples across multiple cancers (n = 290) and longitudinal cohorts of colorectal cancer (CRC, n = 64), and hepatocellular carcinoma (HCC, n = 47).

RESULTS: Optimal parameters to maximize assay performance included single-stranded DNA ligation technology, cfDNA input ≥ 15 ng, post-UMI sequencing depth ≥ 2500X, and high number of tracked mutations. In the tumor-informed setting, the HYB workflow was modestly better than the AMP method in detection of pre-treatment ctDNA; addition of GW features was marginally beneficial except in lung cancer. Surveillance ctDNA determined by the HYB workflow had superior sensitivity to predict recurrence in both CRC (AMP: 90.0%, HYB: 100%) and HCC (AMP: 80.0%, HYB: 96.0%). In the tumor-naïve setting, the performance gap widened significantly, and the combined HYB and GW workflow showed the highest performance in baseline ctDNA detection across all cancers, and achieved sensitivity of 90.0% and 92.0% to detect recurrence in CRC and HCC respectively.

CONCLUSIONS: The new methodology offers a streamlined and scalable solution for both comprehensive liquid biopsy profiling and longitudinal MRD tracking in routine clinical practice.

PMID:42830887 | PMC:PMC13634064 | DOI:10.1016/j.jlb.2026.100496

Role of circulating tumour DNA in predicting complete clinical response and local regrowth after total neoadjuvant therapy for rectal cancer: meta-analysis

MRD

By: Nikhil Lal · Siddharth Shukla · Nicola Hodges · Gina Brown · John T Jenkins

5 October 2026 at 18:00

BJS Open. 2026 Sep 4;10(5):zrag142. doi: 10.1093/bjsopen/zrag142.

ABSTRACT

BACKGROUND: Non-operative management after total neoadjuvant therapy (TNT) has emerged as a potential strategy for patients with locally advanced rectal cancer (LARC) achieving clinical complete response (cCR). Circulating tumour DNA (ctDNA) has been proposed as a systemic biomarker to augment response assessment, but its role in predicting cCR and local regrowth remains uncertain.

METHODS: A systematic review and meta-analysis were performed of studies evaluating ctDNA dynamics in patients with LARC undergoing TNT. PubMed, EMBASE, and Web of Science databases were searched from database inception to 31 March 2026. Primary outcomes were the association between post-TNT ctDNA status and cCR and sustained cCR. Pooled odds ratios (ORs) were calculated using a random-effects model.

RESULTS: Six studies comprising 597 patients were included. ctDNA negativity following TNT was associated with higher likelihood of cCR (OR 8.01; 95% confidence interval (c.i.) 1.43 to 44.90; I2 = 27.0%). The association with sustained cCR was not statistically significant (OR 3.46; 95% c.i. 0.03 to 394.64; I2 = 59.9%). Across studies, post-TNT ctDNA positivity was associated with inferior disease-free, distant recurrence-free, and progression-free survival. ctDNA demonstrated high specificity and positive predictive value for residual disease, but low sensitivity for the detection of residual local disease and local regrowth, with a substantial proportion of patients with residual tumour remaining ctDNA negative at restaging.

CONCLUSION: Post-TNT ctDNA positivity may identify patients at increased risk of adverse oncological outcomes. However, ctDNA negativity was not consistently associated with the absence of residual local disease, limiting its utility as an independent determinant of organ preservation eligibility. ctDNA should be interpreted as a complementary tool for systemic risk stratification alongside established anatomical assessment.

PMID:42832577 | DOI:10.1093/bjsopen/zrag142

Assessment of MRD and Longitudinal Monitoring of Post-Surgery Biliary Tract Cancer With a Customized ctDNA Panel

MRD

By: Yoshihito Shinohara · Toru Nakamura · Yasutoshi Kimura · Takeshi Murakami · Shigeyuki Kojima · Toshikazu Yamaguchi · Kanako C Hatanaka · Ryo Okazaki · Yosuke Kitayama · Keita Fukuda · Fabio Pittella-Silva · Yusuke Nakamura · Satoshi Hirano · Siew-Kee Low

5 October 2026 at 18:00

Cancer Sci. 2026 Oct 5:10.1111/cas.70552. doi: 10.1111/cas.70552. Online ahead of print.

ABSTRACT

Biliary tract cancer (BTC) is a rare abdominal cancer with poor prognosis. Circulating tumor DNA (ctDNA) analysis with liquid biopsy offers a minimally invasive approach for cancer detection and disease monitoring. Given limited reports, this study aims to evaluate minimal residual disease (MRD) and longitudinal ctDNA monitoring in BTC patients. A total of 124 BTC patients were enrolled, with 111 evaluable for ctDNA analysis using a tumor-informed approach. Baseline tumor tissue and plasma samples were collected for comprehensive genomic profiling (CGP). A customized ctDNA panel was developed based on CGP of resectable BTC tumors and public genomic databases for MRD assessment and longitudinal monitoring. ctDNA sequencing was performed using ultradeep targeted next-generation sequencing. Associations between ctDNA detection and outcomes were analyzed. Preoperative ctDNA detection was associated with advanced pathological stage and significantly worse relapse-free survival (RFS) and overall survival. Using this ctDNA panel, preoperative ctDNA was detected in 51.4% of cases, with TP53, KRAS, ARID1A, and SMAD4 being the most frequently mutated genes. During longitudinal monitoring, 57.8% of patients showed persistent ctDNA positivity or subsequent ctDNA detection before radiological recurrence. RFS was significantly shorter among patients with ctDNA positivity during longitudinal monitoring than among those with undetectable ctDNA (HR = 9.04; 95% CI, 3.56-23.97; p < 0.001). Our customized panel detected BTC-specific mutations in plasma using liquid biopsy, and ctDNA positivity was strongly associated with recurrence and survival outcomes. This panel has the potential to improve MRD assessment and longitudinal monitoring in BTC, enabling earlier intervention and improved patient stratification.

PMID:42831344 | PMC:PMC13636022 | DOI:10.1111/cas.70552

A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring

MRD

By: Tu Nguyen · Van-Anh Nguyen Hoang · Cang Huynh · Vy Nguyen · Son-Nam H Le · Quang Thinh Trac · Thien-Phuc Nguyen Hoang · Nhat-Anh Dao · Minh Tran Binh Nguyen · Nam Hb Tran · Duy Minh Phan · Hoa Giang · Hoai-Nghia Nguyen · Lan N Tu

5 October 2026 at 18:00

J Liq Biopsy. 2026 Sep 19;14:100496. doi: 10.1016/j.jlb.2026.100496. eCollection 2026 Dec.

ABSTRACT

BACKGROUND: Circulating tumor DNA (ctDNA) analysis has revolutionized minimal residual disease (MRD) monitoring, but conventional tumor-informed amplicon-based sequencing (AMP) is limited by the narrow variant capacity and diversity. Hybrid capture-based sequencing (HYB) is more versatile and enables both tumor-informed and tumor-naïve liquid biopsy profiling.

METHODS: We analytically validated the performance of our novel HYB workflow and VarSURE variant calling pipeline, using reference standards (n = 6), plasma samples of cancer patients (n = 75) and healthy donors (n = 90). Genome-wide (GW) non-mutation features including copy number alterations, fragmentomics, and end-motif signatures were also evaluated to enhance ctDNA-MRD detection. Clinical performance was directly compared against our legacy AMP method (K-TRACK, Gene Solutions), using pre-treatment blood samples across multiple cancers (n = 290) and longitudinal cohorts of colorectal cancer (CRC, n = 64), and hepatocellular carcinoma (HCC, n = 47).

RESULTS: Optimal parameters to maximize assay performance included single-stranded DNA ligation technology, cfDNA input ≥ 15 ng, post-UMI sequencing depth ≥ 2500X, and high number of tracked mutations. In the tumor-informed setting, the HYB workflow was modestly better than the AMP method in detection of pre-treatment ctDNA; addition of GW features was marginally beneficial except in lung cancer. Surveillance ctDNA determined by the HYB workflow had superior sensitivity to predict recurrence in both CRC (AMP: 90.0%, HYB: 100%) and HCC (AMP: 80.0%, HYB: 96.0%). In the tumor-naïve setting, the performance gap widened significantly, and the combined HYB and GW workflow showed the highest performance in baseline ctDNA detection across all cancers, and achieved sensitivity of 90.0% and 92.0% to detect recurrence in CRC and HCC respectively.

CONCLUSIONS: The new methodology offers a streamlined and scalable solution for both comprehensive liquid biopsy profiling and longitudinal MRD tracking in routine clinical practice.

PMID:42830887 | PMC:PMC13634064 | DOI:10.1016/j.jlb.2026.100496

Engineering human multi-organ tissue chip niches for drug absorption, distribution, metabolism, excretion and toxicity prediction

Nature Biomedical Engineering

By: Jiawei Li · Sofia Madrigal Gamboa · Jade T. Chao · Sarah C. Heilshorn · Joseph C. Wu

5 October 2026 at 08:00

Nature Biomedical Engineering, Published online: 05 October 2026; doi:10.1038/s41551-026-01806-4

Multi-organ-on-a-chip systems aim to improve the prediction of human drug responses by replicating organ interactions in vitro. This Review discusses advances in niche-preserving engineering, scalable manufacturing and multimodal readouts needed to make these systems reliable tools.

Selective PET imaging of bacterial infection using a glycosylated <sup>18</sup>F-fluorodeoxyglucose-derived tracer

Nature Biomedical Engineering

By: Sang Hee Lee · Jung Min Kim · Marina López-Álvarez · Anju Wadhwa · Anil P. Bidkar · Junaid Ur Rahim · Joseph Blecha · Robert R. Flavell · Alvaro A. Ordonez · Youngho Seo · Joanne Engel · Michael A. Ohliger · David M. Wilson

5 October 2026 at 08:00

Nature Biomedical Engineering, Published online: 05 October 2026; doi:10.1038/s41551-026-01798-1

A positron emission tomography tracer that directly targets bacterial metabolism by exploiting the phosphotransferase system, a carbohydrate transport pathway absent in mammalian cells, enables selective detection of living bacteria in vivo.

Stereochemical origin of potential hysteresis in lithium metal batteries with lithium-rich cation-disordered rocksalt positive electrodes

Nature Nanotechnology

By: Yu Mei · Fanjie Xia · Hongyi Chen · Yujin Li · Jinqiang Gao · Kefu Zhu · Lunhua He · Si Wu · Hai-Feng Li · Longlong Fan · Chun Zhan · Lianshan Ni · Haoji Wang · Weishun Jian · Kai Wang · Debbie S. Silvester · Craig E. Banks · Jinsong Wu · Wentao Deng · Guoqiang Zou · Hongshuai Hou · Xiaobo Ji

5 October 2026 at 08:00

Nature Nanotechnology, Published online: 05 October 2026; doi:10.1038/s41565-026-02301-2

Multiscale physicochemical and electrochemical characterizations demonstrate that atomic-scale structural distortion and nanoscale short-range ordering govern the thermodynamic and kinetic components of potential hysteresis in Li||DRX cells.